vs
IMMUCELL CORP（ICCC）与MYRIAD GENETICS INC（MYGN）财务数据对比。点击上方公司名可切换其他公司
MYRIAD GENETICS INC的季度营收约是IMMUCELL CORP的38.1倍（$209.8M vs $5.5M）。MYRIAD GENETICS INC同比增速更快（-0.4% vs -8.4%）。过去两年IMMUCELL CORP的营收复合增速更高（3.9% vs 1.9%）
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
麦利亚德基因公司是总部位于美国犹他州盐湖城的美国基因检测与精准医疗企业。公司拥有多项自主专利技术，帮助医生与患者了解人类疾病的遗传基础，以及基因在疾病发生、发展和治疗中发挥的作用，相关成果可用于开发评估患病风险、指导疾病诊疗的新产品。
ICCC vs MYGN — 直观对比
营收规模更大
MYGN
是对方的38.1倍
$5.5M
营收增速更快
MYGN
高出8.0%
-8.4%
两年增速更快
ICCC
近两年复合增速
1.9%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $209.8M |
| 净利润 | $-139.7K | — |
| 毛利率 | 42.9% | 70.0% |
| 营业利润率 | 0.4% | -2.7% |
| 净利率 | -2.5% | — |
| 营收同比 | -8.4% | -0.4% |
| 净利润同比 | 80.1% | — |
| 每股收益（稀释后） | $-0.02 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICCCMYGN
| Q4 25 | — | $209.8M | ||
| Q3 25 | $5.5M | $205.7M | ||
| Q2 25 | $6.4M | $213.1M | ||
| Q1 25 | $8.1M | $195.9M | ||
| Q4 24 | $7.8M | $210.6M | ||
| Q3 24 | $6.0M | $213.3M | ||
| Q2 24 | $5.5M | $211.5M | ||
| Q1 24 | $7.3M | $202.2M |
净利润ICCCMYGN
| Q4 25 | — | — | ||
| Q3 25 | $-139.7K | $-27.4M | ||
| Q2 25 | $501.9K | $-330.5M | ||
| Q1 25 | $1.4M | $-100.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-701.7K | $-22.1M | ||
| Q2 24 | $-1.5M | $-36.7M | ||
| Q1 24 | $-437.9K | $-26.0M |
毛利率ICCCMYGN
| Q4 25 | — | 70.0% | ||
| Q3 25 | 42.9% | 69.9% | ||
| Q2 25 | 43.7% | 71.2% | ||
| Q1 25 | 41.6% | 68.5% | ||
| Q4 24 | 36.5% | 71.7% | ||
| Q3 24 | 26.3% | 70.2% | ||
| Q2 24 | 22.5% | 69.6% | ||
| Q1 24 | 31.6% | 68.1% |
营业利润率ICCCMYGN
| Q4 25 | — | -2.7% | ||
| Q3 25 | 0.4% | -11.3% | ||
| Q2 25 | 8.8% | -154.5% | ||
| Q1 25 | 13.9% | -14.8% | ||
| Q4 24 | 8.0% | -18.6% | ||
| Q3 24 | -9.6% | -9.4% | ||
| Q2 24 | -25.3% | -17.3% | ||
| Q1 24 | -4.1% | -13.8% |
净利率ICCCMYGN
| Q4 25 | — | — | ||
| Q3 25 | -2.5% | -13.3% | ||
| Q2 25 | 7.8% | -155.1% | ||
| Q1 25 | 17.9% | -0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -11.7% | -10.4% | ||
| Q2 24 | -28.0% | -17.4% | ||
| Q1 24 | -6.0% | -12.9% |
每股收益（稀释后）ICCCMYGN
| Q4 25 | — | $-0.09 | ||
| Q3 25 | $-0.02 | $-0.29 | ||
| Q2 25 | $0.06 | $-3.57 | ||
| Q1 25 | $0.16 | $0.00 | ||
| Q4 24 | $0.09 | $-0.47 | ||
| Q3 24 | $-0.09 | $-0.24 | ||
| Q2 24 | $-0.20 | $-0.41 | ||
| Q1 24 | $-0.06 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.9M | $149.6M |
| 总债务越低越好 | $9.5M | $119.9M |
| 股东权益账面价值 | $29.8M | $368.0M |
| 总资产 | $45.7M | $706.6M |
| 负债/权益比越低杠杆越低 | 0.32× | 0.33× |
8季度趋势，按日历期对齐
现金及短期投资ICCCMYGN
| Q4 25 | — | $149.6M | ||
| Q3 25 | $3.9M | $145.4M | ||
| Q2 25 | — | $74.4M | ||
| Q1 25 | — | $91.8M | ||
| Q4 24 | $3.8M | $102.4M | ||
| Q3 24 | — | $99.9M | ||
| Q2 24 | $1.3M | $97.3M | ||
| Q1 24 | $960.3K | $104.3M |
总债务ICCCMYGN
| Q4 25 | — | $119.9M | ||
| Q3 25 | $9.5M | $119.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $9.0M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $9.8M | — | ||
| Q1 24 | $10.2M | — |
股东权益ICCCMYGN
| Q4 25 | — | $368.0M | ||
| Q3 25 | $29.8M | $372.8M | ||
| Q2 25 | $29.9M | $388.1M | ||
| Q1 25 | $29.0M | $704.9M | ||
| Q4 24 | $27.5M | $701.1M | ||
| Q3 24 | $26.4M | $731.7M | ||
| Q2 24 | $23.5M | $740.5M | ||
| Q1 24 | $24.6M | $760.0M |
总资产ICCCMYGN
| Q4 25 | — | $706.6M | ||
| Q3 25 | $45.7M | $728.1M | ||
| Q2 25 | $46.7M | $677.3M | ||
| Q1 25 | $45.6M | $1.0B | ||
| Q4 24 | $45.1M | $1.0B | ||
| Q3 24 | $44.4M | $1.1B | ||
| Q2 24 | $41.9M | $1.1B | ||
| Q1 24 | $43.1M | $1.1B |
负债/权益比ICCCMYGN
| Q4 25 | — | 0.33× | ||
| Q3 25 | 0.32× | 0.32× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.42× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $10.6M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | — |
| 自由现金流率自由现金流/营收 | -32.3% | — |
| 资本支出强度资本支出/营收 | 10.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $715.4K | — |
8季度趋势，按日历期对齐
经营现金流ICCCMYGN
| Q4 25 | — | $10.6M | ||
| Q3 25 | $-1.2M | $21.1M | ||
| Q2 25 | $1.6M | $-13.6M | ||
| Q1 25 | $1.6M | $-16.3M | ||
| Q4 24 | $-3.1K | $6.6M | ||
| Q3 24 | $-639.3K | $700.0K | ||
| Q2 24 | $581.8K | $2.6M | ||
| Q1 24 | $418.5K | $-18.6M |
自由现金流ICCCMYGN
| Q4 25 | — | — | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $-199.3K | — | ||
| Q3 24 | $-727.7K | — | ||
| Q2 24 | $471.0K | — | ||
| Q1 24 | $348.1K | — |
自由现金流率ICCCMYGN
| Q4 25 | — | — | ||
| Q3 25 | -32.3% | — | ||
| Q2 25 | 22.4% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | -12.1% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 4.8% | — |
资本支出强度ICCCMYGN
| Q4 25 | — | — | ||
| Q3 25 | 10.8% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.0% | — |
现金转化率ICCCMYGN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.19× | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
